Primary gonadal damage following treatment of brain tumors in childhood.
dc.contributor.author | Ahmed, S Rafeeq | |
dc.contributor.author | Shalet, Stephen M | |
dc.contributor.author | Campbell, Richard H A | |
dc.contributor.author | Deakin, David P | |
dc.date.accessioned | 2014-12-22T15:12:16Z | |
dc.date.available | 2014-12-22T15:12:16Z | |
dc.date.issued | 1983-10 | |
dc.identifier.citation | Primary gonadal damage following treatment of brain tumors in childhood. 1983, 103 (4):562-5 J Pediatr | en |
dc.identifier.issn | 0022-3476 | |
dc.identifier.pmid | 6620016 | |
dc.identifier.uri | http://hdl.handle.net/10541/337513 | |
dc.description.abstract | Gonadal function was studied in two groups of children previously treated for medulloblastoma with surgery followed by postoperative craniospinal irradiation. In group 1 but not in group 2, the children also received adjuvant chemotherapy for one to two years. All children in group 1 received a nitrosourea (BCNU or CCNU), plus vincristine in four and procarbazine in three patients. The nine children in group 1 showed clinical and biochemical evidence of gonadal damage with elevated serum FSH concentrations and, in the boys, small testes for their stage of pubertal development. In group 2 (n = 8), each child had completed pubertal development normally, the boys had adult sized testes and the girls regular menses. Gonadotropin values were normal in all eight children. We conclude that nitrosoureas were responsible for the gonadal damage in the children in group 1, with procarbazine also contributing to the damage in the three children who received this drug. In view of the limited proved value of adjuvant chemotherapy with nitrosoureas in the treatment of medulloblastoma, recognition of this serious complication of cytotoxic drug therapy may necessitate reassessing in which subgroups of children with medulloblastoma the benefits of adjuvant chemotherapy outweight the complications. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The Journal of pediatrics | en |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Cerebellar Neoplasms | |
dc.subject.mesh | Child | |
dc.subject.mesh | Child, Preschool | |
dc.subject.mesh | Combined Modality Therapy | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Medulloblastoma | |
dc.subject.mesh | Ovary | |
dc.subject.mesh | Postoperative Care | |
dc.subject.mesh | Puberty | |
dc.subject.mesh | Radiation Injuries | |
dc.subject.mesh | Testis | |
dc.title | Primary gonadal damage following treatment of brain tumors in childhood. | en |
dc.type | Article | en |
dc.contributor.department | Departments of Endocrinology, Paediatric Oncology and Radiotherapy, Christie Hospital and Holt Radium Institute, Manchester | en |
dc.identifier.journal | Journal of Pediatrics | en |
html.description.abstract | Gonadal function was studied in two groups of children previously treated for medulloblastoma with surgery followed by postoperative craniospinal irradiation. In group 1 but not in group 2, the children also received adjuvant chemotherapy for one to two years. All children in group 1 received a nitrosourea (BCNU or CCNU), plus vincristine in four and procarbazine in three patients. The nine children in group 1 showed clinical and biochemical evidence of gonadal damage with elevated serum FSH concentrations and, in the boys, small testes for their stage of pubertal development. In group 2 (n = 8), each child had completed pubertal development normally, the boys had adult sized testes and the girls regular menses. Gonadotropin values were normal in all eight children. We conclude that nitrosoureas were responsible for the gonadal damage in the children in group 1, with procarbazine also contributing to the damage in the three children who received this drug. In view of the limited proved value of adjuvant chemotherapy with nitrosoureas in the treatment of medulloblastoma, recognition of this serious complication of cytotoxic drug therapy may necessitate reassessing in which subgroups of children with medulloblastoma the benefits of adjuvant chemotherapy outweight the complications. |